Organon (OGN) Liabilities and Shareholders Equity (2020 - 2026)

Organon's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $13.0 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 1.22% year-over-year to $13.0 billion; the TTM figure through Mar 2026 stood at $52.9 billion (up 3.42% YoY), while the FY2025 annual figure was $12.9 billion, down 1.79% from the prior year.
• Liabilities and Shareholders Equity was $13.0 billion for Q1 2026 at Organon, up from $12.9 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $13.6 billion in Q3 2025 to a low of $10.4 billion in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $12.0 billion across 5 years, with a median of $12.1 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity declined 7.92% in 2022, then advanced 15.8% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $11.0 billion in 2022, then rose by 10.07% to $12.1 billion in 2023, then grew by 8.65% to $13.1 billion in 2024, then retreated by 1.79% to $12.9 billion in 2025, then increased by 1.0% to $13.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $13.0 billion (Q1 2026), $12.9 billion (Q4 2025), and $13.6 billion (Q3 2025), per Business Quant data.